NCT02705820View on ClinicalTrials.gov

Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG

Pembrolizumab

Switch maintenance pembrolizumab treatment

Trial Locations (1)

2006

Bank of Cyprus Oncology Centre, Nicosia

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Bank of Cyprus Oncology Centre

OTHER

NCT02705820 - Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy | Biotech Hunter | Biotech Hunter